Epidemiologic and Clinical Characteristics of 26 Cases of COVID-19 Arising from Patient-to-Patient Transmission in Liaocheng, China

Figures & data

Table 1 Demographics and Baseline Characteristics of 26 Patients with COVID-19 in Liaocheng Infectious Disease Hospital (Jan 31–Feb 12, 2020)

	n=26
Age (y)	42.0 (33.5–53.3)
Sex (Female/male)	15/11
Smoking, n (%)	5 (19.2%)
Occupation, n (%)
Staff	16 (61.5%)
Agricultural worker	2 (7.7%)
Self-employed	1 (3.9%)
Retired	4 (15.4%)
Student	3 (11.5%)
Comorbidity, n (%)
Hypertension	5 (19.2%)
Diabetes	3 (11.5%)
Cardiovascular and cerebrovascular diseases	2 (7.7%)
Malignant tumour	1 (3.9%)
HIV infection	1 (3.9%)
Previous surgeries	2 (7.7%)
More than one comorbidity	3 (11.5%)

Note: Variables presented as median (interquartile range) or number of patients, n (%).

Abbreviation: HIV, human immunodeficiency virus.

Table 2 Clinical Characteristics and Treatment of 26 Patients with COVID-19 in Liaocheng Infectious Disease Hospital (Jan 31–Feb 12, 2020)

	n=26
Time from onset to admission (d)	4.5 (0.0–7.3)
Signs and Symptoms at Admission, n (%)
Fever	14 (53.9%)
Cough	8 (30.8%)
Expectoration	6 (23.1%)
Shortness of breath	1 (3.9%)
Sore throat	3 (11.5%)
Fatigue	2 (7.7%)
Headache	1 (3.9%)
Rhinorrhoea	2 (7.7%)
Diarrhoea	0 (0.0%)
More than one sign or symptom	12 (46.2%)
No sign or symptom	7 (26.9%)
Contact with individuals from Wuhan, n (%)	2 (7.7%)
Chest CT Findings, n (%)
Unilateral pneumonia	9 (34.6%)
Bilateral pneumonia	15 (57.7%)
Treatment, n (%)
Antiviral treatment	26 (100.0%)
Antibiotic treatment	13 (50.0%)
Chinese medicine	20 (76.9%)
Glucocorticoids	1 (3.9%)
Gastric mucosal protection	5 (19.2%)
Immunotherapy	2 (7.7%)
Oxygen therapy	3 (11.5%)
More than one treatment,	25 (96.2%)

Note: Variables presented as median (interquartile range) or number of patients, n (%).

Table 3 Laboratory Results of 26 Patients with COVID-19 in Liaocheng Infectious Disease Hospital (Jan 31–Feb 12, 2020)

	n=26
Blood Routine
Leucocytes (× 10⁹/L; normal range 4.0–10.0)	5.3 (4.3–6.6)
Increased	1 (3.9%)
Decreased	5 (19.2%)
Neutrophils (× 10⁹/L; normal range 2.0–7.7)	3.7 (2.8–4.9)
Increased	2 (7.7%)
Decreased	3 (11.5%)
Lymphocytes (× 10⁹/L; normal range 0.8–4.0)	0.8 (0.6–1.4)
Decreased	11 (42.3%)
Monocyte (× 10⁹/L; normal range 0.12–0.8)	0.4 (0.3–0.6)
Increased	1 (3.9%)
Platelets (× 10⁹/L; normal range 100.0–300.0)	191.0 (156.8–250.3)
Increased	4 (15.4%)
Haemoglobin (g/L; normal range 110.0–160.0)	140.0 (120.8–153.3)
Increased	2 (7.7%)
Decreased	5 (19.2%)
Coagulation Function
Prothrombin time (s; normal range 11.0–14.0)	12.6 (12.2–13.1)
Increased	2 (7.7%)
Decreased	1 (3.9%)
Activated partial thromboplastin time (s; normal range 22.0–38.0)	28.7 (25.5–33.5)
Increased	2 (7.7%)
Decreased	2 (7.7%)
D-dimer (µg/mL; normal range 0.0–1.0)	0.3 (0.2–0.4)
Increased	1 (3.9%)
Blood Biochemistry
Albumin (g/L; normal range 35.0–55.0)	38.7 (35.7–40.6)
Decreased	5 (19.2%)
Alanine aminotransferase (U/L; normal range 0.0–40.0)	18.0 (14.0–23.0)
Aspartate aminotransferase (U/L; normal range 0.0–40.0)	19.5 (16.8–21.3)
Total bilirubin (μmol/L; normal range 0.0–21.0)	12.2 (10.3–16.3)
Increased	1 (3.9%)
Blood urea nitrogen (mmol/L; normal range 1.69–8.34)	3.2 (2.7–3.5)
Decreased	1 (3.9%)
Serum creatinine (μmol/L; normal range 44.0–97.0)	55.6 (42.0–61.6)
Decreased	7 (26.9%)
Creatine kinase (U/L; normal range 24.0–194.0)	67.5 (50.8–88.8)
Lactate dehydrogenase (U/L; normal range 109.0–245.0)	216.5 (180.5–240.3)
Increased	6 (23.1%)
Creatine kinase-MB (U/L; normal range 0.0–2 5.0)	13.0 (11.0–17.0)
Increased	2 (7.7%)
Glucose (mmol/L; normal range 3.90–6.44)	5.1 (4.9–5.6)
Increased	4 (15.4%)
Infection-Related Biomarkers
Procalcitonin (ng/mL; normal range 0.0–0.05)	0.2 (0.1–0.3)
Increased	24 (92.3%)
Hypersensitive C-reactive protein (mg/L; normal range 0.5–10.0)	11.5 (1.4–28.7)
Increased	14 (53.9%)
Serum amyloid A (mg/L; normal range 0.0–10.0)	12.7 (5.0–66.9)
Increased	16 (61.5%)

Note: Variables presented as median (interquartile range) or number of patients, n (%).